Latest news with #ICI
Fashion Network
an hour ago
- Business
- Fashion Network
Nick Weatherill is new Better Cotton CEO
Global not-for-profit organisation Better Cotton on Thursday named Nick Weatherill as its new CEO. The world's largest cotton sustainability initiative will now be led by the Briton who's a former executive director of the International Cocoa Initiative (ICI). He replaces Alan McClay, who's been leading the organisation for the past decade and announced his plan to step down at the end of last year. Better Cotton said that in his previous role "he led efforts to drive impactful, scalable solutions across the cocoa supply chain'. It added that he 'has a strong record of promoting sustainability and human rights in global supply chains'. Based in Geneva, Switzerland, he's also provided valuable consultancy for organisations such as the International Trade Centre – the joint agency of the United Nations and World Trade Organisation supporting sustainable and inclusive trade in developing countries. He's an English Language and Literature graduate from the University of Oxford and has a master's degree from the London School of Economics and Political Science (LSE). Weatherill said of his new role: 'Better Cotton is the most important reference in sustainability in the cotton industry, a position that makes its work vital for the whole sector, today and in the years to come. I look forward to leading the organisation at a moment when it increases its impact on the quality of cotton and the livelihoods of millions of farmers and workers around the world, building on the fantastic work Alan has done over the past 10 years.' The change in leadership happens at a time when Better Cotton is making significant progress in its global activities. In 2023, the organisation launched its traceability solution, allowing Physical Better Cotton to be traced back to its country of origin, and in early 2025, it announced it had become a certification scheme, ensuring greater transparency through the supply chain. McClay and Weatherill will work together over the course of June to ensure a smooth transition in the leadership of Better Cotton. Both will be present at the organisation's conference in İzmir, Türkiye, on 18-19 June.
Fashion Network
3 hours ago
- Business
- Fashion Network
Nick Weatherill is new Better Cotton CEO
Global not-for-profit organisation Better Cotton on Thursday named Nick Weatherill as its new CEO. The world's largest cotton sustainability initiative will now be led by the Briton who's a former executive director of the International Cocoa Initiative (ICI). He replaces Alan McClay, who's been leading the organisation for the past decade and announced his plan to step down at the end of last year. Better Cotton said that in his previous role "he led efforts to drive impactful, scalable solutions across the cocoa supply chain'. It added that he 'has a strong record of promoting sustainability and human rights in global supply chains'. Based in Geneva, Switzerland, he's also provided valuable consultancy for organisations such as the International Trade Centre – the joint agency of the United Nations and World Trade Organisation supporting sustainable and inclusive trade in developing countries. He's an English Language and Literature graduate from the University of Oxford and has a master's degree from the London School of Economics and Political Science (LSE). Weatherill said of his new role: 'Better Cotton is the most important reference in sustainability in the cotton industry, a position that makes its work vital for the whole sector, today and in the years to come. I look forward to leading the organisation at a moment when it increases its impact on the quality of cotton and the livelihoods of millions of farmers and workers around the world, building on the fantastic work Alan has done over the past 10 years.' The change in leadership happens at a time when Better Cotton is making significant progress in its global activities. In 2023, the organisation launched its traceability solution, allowing Physical Better Cotton to be traced back to its country of origin, and in early 2025, it announced it had become a certification scheme, ensuring greater transparency through the supply chain. McClay and Weatherill will work together over the course of June to ensure a smooth transition in the leadership of Better Cotton. Both will be present at the organisation's conference in İzmir, Türkiye, on 18-19 June.
Fashion Network
3 hours ago
- Business
- Fashion Network
Nick Weatherill is new Better Cotton CEO
Global not-for-profit organisation Better Cotton on Thursday named Nick Weatherill as its new CEO. The world's largest cotton sustainability initiative will now be led by the Briton who's a former executive director of the International Cocoa Initiative (ICI). He replaces Alan McClay, who's been leading the organisation for the past decade and announced his plan to step down at the end of last year. Better Cotton said that in his previous role "he led efforts to drive impactful, scalable solutions across the cocoa supply chain'. It added that he 'has a strong record of promoting sustainability and human rights in global supply chains'. Based in Geneva, Switzerland, he's also provided valuable consultancy for organisations such as the International Trade Centre – the joint agency of the United Nations and World Trade Organisation supporting sustainable and inclusive trade in developing countries. He's an English Language and Literature graduate from the University of Oxford and has a master's degree from the London School of Economics and Political Science (LSE). Weatherill said of his new role: 'Better Cotton is the most important reference in sustainability in the cotton industry, a position that makes its work vital for the whole sector, today and in the years to come. I look forward to leading the organisation at a moment when it increases its impact on the quality of cotton and the livelihoods of millions of farmers and workers around the world, building on the fantastic work Alan has done over the past 10 years.' The change in leadership happens at a time when Better Cotton is making significant progress in its global activities. In 2023, the organisation launched its traceability solution, allowing Physical Better Cotton to be traced back to its country of origin, and in early 2025, it announced it had become a certification scheme, ensuring greater transparency through the supply chain. McClay and Weatherill will work together over the course of June to ensure a smooth transition in the leadership of Better Cotton. Both will be present at the organisation's conference in İzmir, Türkiye, on 18-19 June.
Business Wire
3 days ago
- Business
- Business Wire
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced initial Phase 1 safety and efficacy data from the Phase 1/2 Agni-01 multicenter study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma (NCT06060613). These data, summarized below, will be presented in a rapid oral presentation (abstract 9517) delivered by Jason A. Chesney, M.D., Ph.D., Director and Chief Administrative Officer of UofL Health – Brown Cancer Center/Oncology Service Line at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Obsidian is also presenting a poster for abstract 9519 summarizing translational data from the Phase 1 first-in-human single-center study of OBX-115 (NCT05470283, enrollment completed) in ICI-resistant advanced melanoma. Summary of OBX-115 Safety and Efficacy Data (March 26, 2025 data cutoff): Advancing a More Patient-centric TIL Cell Therapy Regimen in Heavily Pre-treated Advanced Melanoma Patient Population Patients had disease that was predominantly ICI primary-resistant, with a median of 4 (range, 1–6) lines of prior systemic therapy, including a median of 2 (1–5) lines of prior ICI therapy (n=11). 10 patients received low-dose lymphodepletion (approximately 50% less Cyclophosphamide relative to non-engineered TIL), including 1 in the outpatient setting. Acetazolamide (ACZ) redosing following initial OBX-115 infusion to drive re-activation of OBX-115 cells was tolerable and safe enough to administer at home. OBX-115 Continues to Deliver Positively Differentiated Safety Profile Relative to Non-engineered TIL; No IL2, No Treatment-related Mortality: No dose-limiting toxicities were observed at any dose level. No Grade 4 or higher nonhematologic treatment-related adverse events (TRAEs) were reported; 5 patients experienced limited Grade 3 nonhematologic TRAEs. No confirmed events of cytokine release syndrome or infusion-related reaction higher than Grade 2; no capillary leak syndrome or immune effector cell-associated neurotoxicity syndrome were reported. No treatment-related ICU transfer, no treatment-related mortality. OBX-115 Maintains Consistent Efficacy Profile Without IL2 and With Low-dose Lymphodepletion in Anti-PD-1-resistant Advanced Melanoma; Dose Level 3 (RP2D) To Be Further Explored in Phase 2 Encouraging efficacy profile observed at the RP2D (n=6) 66.7% ORR, including 1 confirmed CR and 3 confirmed PRs (investigator-assessed RECIST 1.1 criteria) Durable clinical benefit, including 3 of 4 responses ongoing at week 24 / data cutoff (median duration of response not reached) 100% disease control rate, defined as stable disease or better for ≥12 weeks post-infusion 36.4% objective response rate (ORR) across all dose levels (n=11) Majority had reduction in tumor burden reduction: 83% at RP2D; 73% across all dose levels. Dr. Chesney commented, 'It is very encouraging to see the promising safety and efficacy profile for OBX-115, now observed in the Agni-01 multicenter study. As a highly differentiated, IL2-sparing TIL cell therapy that is compatible with low-dose lymphodepletion, OBX-115 has the potential to transform the treatment landscape and broaden the eligible population for patients with high unmet need.' 'The exciting results from OBX-115 in ICI-resistant advanced melanoma further indicate that OBX-115 has promising therapeutic potential, and that ACZ redosing is well-tolerated and has the potential to re-activate and re-expand persistent OBX-115 TIL,' commented Parameswaran Hari, M.D., Chief Development Officer of Obsidian. 'We look forward to exploring the go-forward melanoma RP2D in Phase 2, and continuing to evaluate OBX-115 in a Phase 1 cohort of patients with advanced non-small cell lung cancer, where we believe the potential impact from an IL2-sparing TIL cell therapy is clinically significant and may expand patient eligibility.' Obsidian is actively enrolling patients with advanced or metastatic melanoma and non-small cell lung cancer (NSCLC) at multiple sites in its ongoing Phase 1/2 Agni-01 multicenter study. Additional details may be found at using identifier: NCT06060613. About OBX-115 Obsidian's lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian's proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. Obsidian is investigating OBX-115 in the phase 1/2 Agni-01 multicenter trial in patients with advanced solid tumors (NCT06060613). About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. For more information, please visit and follow us on LinkedIn.
Business Wire
3 days ago
- Business
- Business Wire
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). It is currently available for research use only, with clinical availability expected later this year. In 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, with a corresponding estimated response rate of 20.13%. 1 xM for TRM is designed to quantify changes in circulating tumor DNA (ctDNA) longitudinally from a blood sample, enabling early molecular response assessment in patients with advanced cancers receiving immunocheckpoint inhibitors (ICI) alone or combination therapies. xM for TRM leverages a unique multi-parametric algorithm, integrating copy number variations (CNVs), along with somatic and germline variant allele frequencies (VAFs), for a comprehensive and robust estimation of circulating tumor fraction. Tempus is presenting new data on xM for TRM at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, highlighting the assay's potential to help clinicians monitor response and refine treatment strategies for patients with advanced cancers. Title: A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Location: Poster Section Developmental Therapeutics—Immunotherapy (Poster #205) Overview: Tempus xM for TRM, a liquid biopsy test, monitors treatment response by tracking ctDNA dynamics over time. Longitudinal non-molecular responders are associated with worse survival compared to molecular responders, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. 'Our comprehensive monitoring portfolio is designed to support patients throughout the cancer treatment journey,' said Halla Nimeiri, MD, Chief Development Officer at Tempus. 'We're excited to introduce a new assay of molecular response for both physicians and biopharma researchers that can timely track changes of quantitative tumor fraction while patients receive ICI therapies. This may impact treatment decisions, especially for patients with advanced disease, where timing is absolutely critical. With xM for TRM, clinicians can detect molecular response to ICI prior to six weeks into treatment, enabling them to stay ahead of disease progression and optimize therapeutic strategies.' About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of xM TRM and other tests, the indicated use of the xM TRM and other tests for potential clinical use, and the timing of the availability of such testing, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
